Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002586 · ClinicalTrials.gov registry record · Phase 2
13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT00002586: Completed Phase 2 study, sponsored by University of Colorado, Denver.
NCT00002586 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 96 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002586, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.
Primary Outcome
Treatment "failure" defined as histologic progression (any increase in the maximum histologic score) or failure to return for follow-up bronchoscopy
Interventions
- DRUG 13-cis retinoic acid
- DIETARY_SUPPLEMENT Tocopherol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 1993-01 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
What the finished NCT00002586 record still lists
NCT00002586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 96 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (28% lower).
The record links to 0 conditions, and to 2 interventions - of which 13-cis retinoic acid is the first listed.
NCT00002586 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002586 about?
NCT00002586 is a clinical study titled "13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer". RATIONALE: 13 Cis retinoic acid may prevent the development of cancer cells. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of 13-cis retinoic acid with or without vitamin E for chemoprevention or observation of cancer in persons at high risk of developing lung cancer.
What is the current status of trial NCT00002586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 1993-01. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00002586?
The interventions under investigation include: 13-cis retinoic acid (DRUG), Tocopherol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00002586?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002586's enrollment target sits among peer trials
96 747th of 2000 higher than 1,242 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03401762 · 96 participants · NA
Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke
- NCT03471260 · 96 participants · Phase 1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- NCT03549559 · 96 participants · NA
Imaging Histone Deacetylase in the Heart
- NCT03841058 · 96 participants · Phase 2
Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia